Feasibility Study of a Human Papillomavirus E6 Oncoprotein Test for Diagnosis of Cervical Precancer and Cancer
Feasibility Study of a Human Papillomavirus E6 Oncoprotein Test for Diagnosis of Cervical Precancer and Cancer
复制标题
DOI：
10.1128/jcm.01315-10
复制
发表时间：
2010-12-01
影响因子：
9.4
通讯作者：
Castle, Philip E.
中科院分区：
文献类型：
--
作者：
Schweizer, Johannes;Lu, Peter S.;Castle, Philip E.
在一项使用原型的可行性研究中，侧流检测人乳头瘤病毒16、18和/或45型（HPV 16/18/45）E6癌蛋白，51/75（占68%;来自诊断为CIN 3+的女性的HPV 16/18/45 DNA阳性标本的95%置信区间[95% CI]为56%至78%）（宫颈上皮内瘤变3+级或宫颈癌）HPV 16/18/45 E6癌蛋白检测阳性。16例（95% CI为0 - 37%）HPV 16/18/45 DNA阳性的宫颈标本均未检测出HPV 16/18/45 E6癌蛋白阳性。
In a feasibility study using a prototype, lateral-flow test for human papillomavirus type 16, 18, and/or 45 (HPV16/18/45) E6 oncoproteins, 51 of 75 (68%; 95% confidence interval [95% CI] of 56 to 78%) of HPV16/18/45 DNA-positive specimens from women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical cancer) tested positive for HPV16/18/45 E6 oncoprotein. None of 16 (95% CI of 0 to 37%) HPV16/18/45 DNA-positive cervical specimens from women with a negative or CIN1 diagnosis tested positive for HPV16/18/45 E6 oncoprotein.